Recent research have centered on the convergence of GLP-1|GIP|GCGR activator therapies and DA signaling. While GCGR activators are increasingly employed for addressing type 2 diabetes, their unexpected consequences on reward circuits, specifically mediated by dopaminergic networks, are receiving considerable attention. This report details a concise